EU parliament votes in favour of New Genome Techniques
The European Parliament adopted its position for negotiations with Member States on the Commission's proposal on new genomic techniques (NGTs) in favour for using CRISPR/Cas as a new but now […]
EU parliament backs deregulation of New Genome Techniques
After two "Yes"-votes in the European Parliament’s AGRI and ENVI committees, MEPs confirmed the European Commissions draft Regulation on New Genomic Technologies in plant breeding.<br /> <br /><br /> <br /><br […]
Jazz Pharmaceiticals licences KRAS blocker from Redx Pharma
Jazz Pharmaceuticals plc has entered an agreement with Redx Pharma to acquire commercialisation rights to Redx KRAS blockers, which include G12D selective and pan-KRAS molecules.<br /><br />
Jazz Pharmaceuticals licences KRAS blocker from Redx Pharma
Jazz Pharmaceuticals plc has entered an agreement with Redx Pharma to acquire commercialisation rights to Redx KRAS blockers, which include G12D selective and pan-KRAS molecules.<br /><br />
Spanish plant-based protein producer Heura closes Series B financing
Spanish Food tech Start-up Heura Foods secures €40m in Series B financing round to expand product distribution.<br /><br /><br />
Spanish plant-based protein producer Heüra Foods closes Series B financing
Spanish Food tech Start-up Heüra Foods secures €40m in Series B financing round to expand product distribution.<br /><br /><br />
Biovian and 3P Biopharmaceuticals join forces to create 3PBIOVIAN
Biovian and 3P Biopharmaceuticals have created a new pan-European CDMO, dubbed 3PBIOVIAN. <h2></h2> <h2></h2>
Lonza and Oxford Nanopore collaborate to advance mRNA Therapeutics
To improve mRNA product analysis, the Lonza Group Ltd. and Oxford Nanopore Technologies plc. are working together to develop and market a test to assess multiple critical quality attributes of […]
£26m for Cystic Fibrosis Drug Trial
Enterprise Therapeutics Ltd. has raised £26m for the Phase IIa trial of ETD001, a novel cystic fibrosis treatment, with investment led by Panakes Partners and participation from existing investors.
Alvotech Advances in Biosimilar Market with Successful AVT03 Study
AVT03, a biosimilar candidate for osteoporosis treatment, showed promise in treating bone illnesses, according to results from a pharmacokinetic study by Alvotech SA.